
Core Insights - Biotechnology firms are increasingly focusing on innovative combination therapies for difficult-to-treat cancers, generating significant investor interest, particularly in AIM ImmunoTech Inc. following a positive update from the DURIPANC Phase 2 study [1][5] Company Summary - AIM ImmunoTech is conducting the DURIPANC study, which evaluates Ampligen (rintatolimod) in combination with AstraZeneca's anti-PD-L1 inhibitor, Imfinzi, for metastatic pancreatic cancer patients who have stable disease after FOLFIRINOX treatment [2] - The DURIPANC study is a collaboration with AstraZeneca and Erasmus Medical Center, aiming to enroll up to 25 subjects in its Phase 2 portion [2] - As of the mid-year report, 14 subjects have been enrolled, with the primary objective being to determine the clinical benefit rate of the combination therapy [3] Study Results - The DURIPANC study has shown promising early signs of no significant toxicity, with 21% of patients experiencing progression-free survival (PFS) of over 6 months, and an additional 21% not yet progressed [4][6] - The overall survival (OS) rate for eligible patients is 64% over 6 months, which exceeds expectations for this treatment setting [6] - AIM has secured a U.S. patent for Ampligen as an oncology treatment in combination with an anti-PD-L1, extending protection until August 9, 2039 [4] Market Reaction - Following the positive mid-year report, AIM ImmunoTech shares increased by 36.79%, reaching $11.49 [5]